Loeb Partners’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
– Sell
-200
Closed -$10K – 93
2019
Q1
$10K Hold
200
– – 0.21% 81
2018
Q4
$6K Buy
+200
New +$7.31K ﹤0.01% 245

Other funds holding NVCR

Loeb Partners's NVCR Position: Q2 2019 in Review

Loeb Partners sold out of NovoCure (NVCR) in Q2 2019, closing a stake of 200 shares — an estimated $10K sold.

Loeb Partners first reported a position in NVCR in Q4 2018 and held it in 2 quarters. The position peaked at $10K in Q1 2019. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.

  • Loeb Partners reported no remaining NovoCure position as of Q2 2019 after selling out during the quarter.
  • Loeb Partners sold 200 NovoCure shares in Q2 2019, an estimated $10K.
  • Loeb Partners first reported a position in NovoCure in Q4 2018 and held it in 2 quarters.
  • Loeb Partners's NovoCure position peaked at $10K in Q1 2019.
  • 197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.

Based on Loeb Partners's 13F filing for Q2 2019.